Christopher King is a Neurology physician. ClinicalTrials.gov lists 15 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
905 Hanshaw Road
Suite A
Ithaca, NY 148501871
Telephone
607-273-6757Registry record last updated 17 Apr 2019.
Clinical trials
- Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults
Sponsor: Inova Health Care Services
- Pilot Study for Postoperative Machine Learning
Sponsor: Washington University School of Medicine
- Safety and Efficacy of IDA for Onchocerciasis
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
39 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202511 payments
- PFIZER INC.Program year202510 payments
- Eisai Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
91.4%Aromatic Amino Acid Decarboxylation Inhibitor21.5%Carbidopa-Levodopa61%Carbidopa-Levodopa Er34%Rytary6%Part D<11 patientsGabapentinoids14.3%Gabapentin64%Pregabalin33%Lyrica3%Part D<11 patients+ 23 more classes in this area
Musculoskeletal
3.6%gamma-Aminobutyric Acid-ergic Agonist2.9%Baclofen100%Part D≥19 patientsCentral alpha-2 Adrenergic Agonist0.7%Tizanidine Hcl100%Part D<11 patientsCardiovascular
2.1%Beta blocker1.5%Propranolol Hcl Er69%Propranolol Hcl31%Part D<11 patientsStatin0.6%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”